Skip to main content
Premium Trial:

Request an Annual Quote

NextGxDx Offering PreventionGenetics' Test Catalog

NEW YORK (GenomeWeb News) – NextGxDx will begin offering PreventionGenetics' test catalog through the NextGxDx platform under an agreement announced today.

The deal adds hundreds of new genetic tests "to the NextGxDx marketplace for easy search, comparison, and ordering," NextGxDx said. Financial and other terms of the deal were not disclosed.

"PreventionGenetics adds tremendous depth to our catalog and enhances the choice of genetic testing products available to health care providers through our platform," Judsen Schneider, NextGxDx scientific director, said in a statement. "Given their commitment to the research and development of new genetic testing products, we expect that catalog will continue to expand over time."

Nashville, Tenn.-based NextGxDx said last week it had raised $1 million in a private financing round.

The company offers an online platform that allows healthcare professionals to access listings of genetic tests from CLIA-certified laboratories, order them, and view the test results.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.